AMGEN INC — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
Amgen reported Q3 2026 total revenues of $10.4B (up 8% YoY) and product sales of $9.9B (up 8% YoY). GAAP diluted EPS increased 19% to $7.08 from $5.93; non-GAAP diluted EPS rose 14% to $6.45 from $5.64. Seventeen products delivered double-digit sales growth; seventeen products annualizing >$1B. Free cash flow declined to $3.7B from $4.2B, primarily due to working capital timing. Full-year 2026 guidance: revenues $38.9B–$39.7B; GAAP EPS $18.34–$19.28; non-GAAP EPS $22.90–$23.70.
Why this rating
Solid operational quarter with expected growth; revenue and EPS growth typical for large pharma. No material M&A, strategic shifts, or business-altering events. Routine earnings announcement.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.